Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Neurocrine Biosciences Inc patents

Recent patent applications related to Neurocrine Biosciences Inc. Neurocrine Biosciences Inc is listed as an Agent/Assignee. Note: Neurocrine Biosciences Inc may have other listings under different names/spellings. We're not affiliated with Neurocrine Biosciences Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Neurocrine Biosciences Inc-related inventors

Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a vmat2 inhibitor to a subject in need thereof are provided.. . ... Neurocrine Biosciences Inc

Processes for the preparation of uracil derivatives

. . . . . . The present invention relates to processes and intermediates for preparing gonadotropin-releasing hormone (gnrh) receptor antagonists of structure (vi); and stereoisomers and pharmaceutically acceptable salts thereof.. . ... Neurocrine Biosciences Inc

Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)

Provided herein are processes for the preparation of (s)-(2r,3r,11br-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.. . ... Neurocrine Biosciences Inc

Treatment of hyperkinetic movement disorders

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent vmat2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol ((+)α-htbz) is used in the methods described herein for treating a subject in need thereof.. ... Neurocrine Biosciences Inc

Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Crf1 receptor antagonists have the potential to directly inhibit acth release in patients with cah and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.. . ... Neurocrine Biosciences Inc

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Neurocrine Biosciences Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Neurocrine Biosciences Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by